We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.74%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.87B
AUM Growth
+$435M
Cap. Flow
+$144M
Cap. Flow %
3.71%
Top 10 Hldgs %
35.18%
Holding
133
New
4
Increased
60
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$39.2M
2
BPMC
Blueprint Medicines
BPMC
+$35.9M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$21.8M
4
WST icon
West Pharmaceutical
WST
+$21.2M
5
GOSS icon
Gossamer Bio
GOSS
+$19.7M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$64.6M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$20.5M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$15.4M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$14.2M
5
EPZM
Epizyme, Inc
EPZM
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 96.71%
2 Consumer Staples 0.91%
3 Industrials 0.67%
4 Financials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
51
BioMarin Pharmaceuticals
BMRN
$13.3B
$22.4M 0.58%
264,500
– –
BCRX icon
52
BioCryst Pharmaceuticals
BCRX
$2.51B
$21.6M 0.56%
1,712,507
+251,416
+17% +$3.24M
CYTK icon
53
Cytokinetics
CYTK
$10.8B
$21.5M 0.55%
443,000
+43,000
+11% +$2.07M
MDGL icon
54
Madrigal Pharmaceuticals
MDGL
$11.9B
$20.6M 0.53%
317,485
– –
VERV
55
DELISTED
Verve Therapeutics
VERV
$19.2M 0.5%
558,837
+54,800
+11% +$1.75M
GOSS icon
56
Gossamer Bio
GOSS
$86.1M
$19M 0.49%
+1,586,962
New +$19.7M
EXAS
57
DELISTED
Exact Sciences
EXAS
$18.8M 0.49%
578,600
+5,900
+1% +$243K
CNMD icon
58
CONMED
CNMD
$1.48B
$18.7M 0.48%
233,000
+10,000
+4% +$943K
AURA icon
59
Aura Biosciences
AURA
$796M
$18.4M 0.48%
1,015,757
+6,943
+0.7% +$105K
LEGN icon
60
Legend Biotech
LEGN
$4B
$18.4M 0.47%
450,466
+94,899
+27% +$4.45M
DVAX
61
DELISTED
Dynavax Technologies
DVAX
$17.6M 0.45%
1,683,358
+1,900
+0.1% +$24.8K
OLK
62
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$17.5M 0.45%
1,445,000
+213,200
+17% +$3.27M
WRBY icon
63
Warby Parker
WRBY
$3.26B
$17.5M 0.45%
1,309,475
+35,975
+3% +$479K
IMTX icon
64
Immatics
IMTX
$1.33B
$16.8M 0.43%
1,681,224
+553,254
+49% +$5.97M
ANAB icon
65
AnaptysBio
ANAB
$1.64B
$14.7M 0.38%
576,600
+4,300
+0.8% +$101K
AZTA icon
66
Azenta
AZTA
$1.54B
$14.2M 0.37%
330,200
+168,200
+104% +$10M
RLAY icon
67
Relay Therapeutics
RLAY
$4.37B
$13.8M 0.36%
618,267
– –
NVCR icon
68
NovoCure
NVCR
$2.02B
$13.3M 0.34%
175,000
– –
LFST icon
69
Lifestance Health
LFST
$4.55B
$13.2M 0.34%
2,000,000
– –
ARVN icon
70
Arvinas
ARVN
$588M
$12.5M 0.32%
280,100
– –
CMPX icon
71
Compass Therapeutics
CMPX
$400M
$12.2M 0.31%
5,333,188
+5,100
+0.1% +$14.1K
CLDX icon
72
Celldex Therapeutics
CLDX
$3.37B
$11.9M 0.31%
421,604
+86,127
+26% +$2.64M
COLL icon
73
Collegium Pharmaceutical
COLL
$882M
$11.6M 0.3%
725,000
– –
AMLX icon
74
Amylyx Pharmaceuticals
AMLX
$2.53B
$11.4M 0.29%
403,737
-570,370
-59% -$14.2M
NVAX icon
75
Novavax
NVAX
$1.3B
$10.9M 0.28%
599,300
+124,200
+26% +$5.38M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Rock Springs Capital Management held 133 positions worth $3.87B, up 13% from $3.44B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management deployed $144M of net new capital in Q3 2022, opening 4 new positions and adding to 60 existing holdings. Its largest new stake was Gossamer Bio: 1,586,962 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Shockwave Medical, Inc. Common Stock, an estimated $15.4M trimmed.

  • Rock Springs Capital Management's largest Q3 2022 buy was Gossamer Bio: 1,586,962 shares worth $19M.
  • Rock Springs Capital Management added most to Immunocore in Q3 2022, an estimated $39.2M increase.
  • Rock Springs Capital Management's biggest Q3 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $64.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $3.87B portfolio in Q3 2022.
  • Rock Springs Capital Management opened 4 new positions and closed 5 in Q3 2022.
  • Rock Springs Capital Management's portfolio value rose 13% quarter-over-quarter to $3.87B.

Based on Rock Springs Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.